Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
16.17
+0.11 (0.68%)
Jul 22, 2025, 4:00 PM - Market closed
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Centessa Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $28.9, which forecasts a 78.73% increase in the stock price over the next year. The lowest target is $14 and the highest is $38.
Price Target: $28.9 (+78.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 7 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +85.53% | Jul 21, 2025 |
| Needham | Needham | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +116.45% | May 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +85.53% | May 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $38 | Buy | Initiates | $38 | +135.00% | Mar 31, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +73.16% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
13.91M
Revenue Next Year
n/a
from 13.91M
EPS This Year
-1.33
from -2.06
EPS Next Year
-1.55
from -1.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | n/a | n/a | ||
| Avg | 13.9M | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.25 | -1.24 | -1.14 | ||
| Avg | -1.33 | -1.55 | -1.62 | ||
| Low | -1.47 | -1.77 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.